Tipsheet
What matters at India’s listed companies
Earnings · Healthcare · Micro cap

Kerala Ayurveda reports wider losses despite double-digit revenue growth

The company posted a standalone net loss of ₹14.74 crore for FY26, while auditors flagged mounting receivables from its own subsidiaries.

2 earlier stories on Kerala Ayurveda Ltd.
Mkt cap₹274 cr
ROE0.00%
Debt / eq.6.95
₹20.65 cr Consolidated net loss for the fiscal year ended March 31, 2026.

What's new

  • Standalone revenue climbed 17.6% to ₹85.48 crore, but net losses deepened to ₹14.74 crore.
  • Consolidated revenue reached ₹131.15 crore, a 9% increase, alongside a ₹20.65 crore net loss.
  • Auditors issued an emphasis of matter regarding unprovided trade receivables from subsidiaries.

Why this matters

Revenue growth is failing to translate into profitability, leaving the company with deepening losses. The auditor's focus on unprovided receivables from subsidiaries suggests a potential balance-sheet risk that warrants close attention.

What we're watching

  • Management's plan to address the mounting trade receivables.
  • Any steps to curb the widening consolidated net loss.
  • Future disclosures regarding the recoverability of subsidiary dues.

The full read

Kerala Ayurveda’s latest annual results show a sharp disconnect between top-line growth and bottom-line health. While standalone revenue grew 17.6% to ₹85.48 crore, the company’s net loss widened to ₹14.74 crore.

Consolidated revenue rose 9% to ₹131.15 crore, yet the net loss deepened to ₹20.65 crore. Beyond the numbers, the audit report carries an emphasis of matter regarding significant trade receivables owed by subsidiaries that remain unprovided for in the books. This is a routine annual disclosure, but the combination of persistent losses and unprovided subsidiary debt creates a difficult backdrop for the company's financial position. The next test is how management plans to address these receivables and move toward profitability. It won't be easy.

Questions answered

How did Kerala Ayurveda perform in FY26?
The company saw revenue growth across both segments, with standalone revenue rising 17.6% to ₹85.48 crore and consolidated revenue up 9% to ₹131.15 crore. However, both segments reported losses, with standalone net loss at ₹14.74 crore and consolidated net loss at ₹20.65 crore.
What concern did the auditors raise in the report?
The auditors included an emphasis of matter regarding significant outstanding trade receivables from subsidiaries. The company has not made provisions for these amounts.
Is this a routine disclosure?
Yes, this is a standard annual financial disclosure under SEBI LODR regulations for the year ended March 31, 2026.
Mentioned: Kerala Ayurveda Ltd. · FY26
Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.

  1. 25 May 2026 · 8:07 PM IST Kerala Ayurveda reports wider losses despite double-digit revenue growth
  2. today Kerala Ayurveda reports revenue growth alongside widening annual losses
  3. today Kerala Ayurveda reports revenue growth but losses widen for FY26